IRIS
CANTONETTI, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 31.264
EU - Europa 2.581
AS - Asia 668
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 7
AF - Africa 5
OC - Oceania 5
Totale 34.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.141
DE - Germania 752
CN - Cina 491
UA - Ucraina 423
IT - Italia 338
IE - Irlanda 336
GB - Regno Unito 231
FR - Francia 140
CA - Canada 120
KR - Corea 118
FI - Finlandia 98
SE - Svezia 88
RU - Federazione Russa 66
PL - Polonia 44
BE - Belgio 27
JP - Giappone 11
EU - Europa 10
NL - Olanda 9
CH - Svizzera 8
RO - Romania 8
HK - Hong Kong 6
VN - Vietnam 6
AU - Australia 4
IN - India 4
SG - Singapore 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
BG - Bulgaria 3
KG - Kirghizistan 3
MX - Messico 3
PH - Filippine 3
AR - Argentina 2
BR - Brasile 2
CL - Cile 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
NO - Norvegia 2
SA - Arabia Saudita 2
TG - Togo 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BD - Bangladesh 1
CM - Camerun 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
ES - Italia 1
GR - Grecia 1
KZ - Kazakistan 1
MA - Marocco 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
TH - Thailandia 1
TR - Turchia 1
Totale 34.541
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.266
Wilmington 8.715
Houston 7.669
Ann Arbor 810
Fairfield 769
Chandler 585
Ashburn 429
Jacksonville 389
Seattle 331
Dublin 322
New York 291
Cambridge 279
Medford 237
Beijing 222
Dearborn 198
Rome 132
Munich 127
Lawrence 114
Mcallen 111
Montréal 110
Zhengzhou 71
Mülheim 68
Menlo Park 52
San Diego 42
Kraków 40
Milan 35
Hefei 33
Shanghai 24
University Park 23
Norwalk 21
Brussels 20
Mountain View 20
Saint Petersburg 20
Nanjing 19
London 18
Creede 16
Guangzhou 16
Redwood City 16
Palo Alto 14
Seoul 14
Falls Church 13
Helsinki 13
Kunming 13
Center 12
Engelhard 11
Nürnberg 11
Verona 10
Bologna 9
Hebei 7
Nanchang 7
Toronto 7
Wuhan 7
Cedarhurst 6
Chicago 6
Detroit 6
Frankfurt am Main 6
Fuzhou 6
Hangzhou 6
Redmond 6
Changsha 5
Kilburn 5
Phoenix 5
Shenyang 5
Amsterdam 4
Chengdu 4
Chongqing 4
Council Bluffs 4
Duncan 4
Fremont 4
Hanoi 4
Hong Kong 4
Los Angeles 4
Manitou Springs 4
Nancy 4
San Jose 4
San Mateo 4
Bari 3
Chaoyang 3
Chiswick 3
Monterotondo 3
Picinisco 3
Sannazzaro de' Burgondi 3
Santa Clara 3
Suceava 3
Turin 3
Alghero 2
Ancenis 2
Auburn Hills 2
Boardman 2
Calgary 2
Canberra 2
Central 2
Dong Ket 2
Durham 2
Easton 2
Grezzana 2
Indiana 2
Islington 2
Jinan 2
Kearney 2
Totale 31.979
Salva come PNG Salva come JPEG
Nome #
Awake thoracoscopic biopsy of anterior mediastinal masses 821
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 487
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 471
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 462
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 437
Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol 429
Treatment of multiple myeloma: A randomized study of three different regimens 427
Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients 419
Non-Hodgkin lymphomas of the central nervous system 412
WILL MOLECULAR-BIOLOGY CONTRIBUTE TO REFINE PROGNOSIS AND TO SELECT TREATMENT 410
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 409
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 405
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 405
Comprehensive analysis of PTEN status in Sezary syndrome 403
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 401
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 399
Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study 398
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial 396
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses 390
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 390
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients 389
Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma 389
Multiple skin tumors in long-term treatment with hydroxyurea 388
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 387
Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? 387
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 386
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion 383
Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease 382
FISH analysis for CML monitoring? 381
Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients 374
SEQUENTIAL THERAPY WITH VAPLD AND BORTEZOMIB AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSION BEFORE STEM CELL MOBILIZATION 374
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group 371
Reduced intensity allogeneic transplantation in primary cutaneous t-cell lymphomas. 366
Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia 365
Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy 364
Menstrual function in patients undergoing chemotherapy for Hodgkin's disease 363
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions. 362
Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma 360
PROGNOSTIC VALUE OF CEREBROSPINAL FLUID FLOW CYTOMETRY ANALYSIS IN AGGRESSIVE NHL PATIENTS AT HIGH RISK FOR LEPTOMENINGEAL DISEASE: FCM plus MAY PREDICT AN HIGH RISK OF CNS RELAPSE 358
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients 357
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: An update 357
Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia 356
EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986 356
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 354
INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA 354
TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE 354
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 353
Biological and clinical advances in multiple myeloma: A review 353
KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML 353
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 353
CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE 351
Psoriasiform sarcoidosis: an unusual variety 351
Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment 348
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial 346
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias 346
Monitoring treatment and survbival in Cronic Myeloid Leukemia 346
EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY 346
Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis 342
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions 342
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 339
Intermediate stage Hodgkin's disease: Preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy 338
CLIPI: A new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 338
Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease 337
Peripheral polyneuropathy during treatment with alpha-2 interferon 336
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma 334
Allogeneic stem cell transplantation for patients with advanced primary cutaneous T-cell lymphoma 331
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 331
Bone marrow processing with a gravity sedimentation technique: experience of 13 cases 325
Reduced-intensity conditioning combined with standard GvHD prophylaxis is tolerable and highly effective for patients with primary cutaneous T-cell lymphomas undergoing allogeneic transplantation in advanced disease stage. 324
Chemotherapy in cutaneous T-cell lymphoma 323
Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients 323
Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study 321
Surgical management of rhinosinusitis in onco-hematological patients 320
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 317
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients 316
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 311
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma 307
Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymph 304
PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION 303
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 299
Initial staging of hodgkin's disease: Role of contrast-enhanced 18F FDG PET/CT 296
Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs 295
Il trattamento chirurgico delle rinosinusiti nei pazienti oncoematologici: confronto tra procedure 292
Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. 290
Early detection of IgH monoclonal rearrangenent in follicular spicules of the nose preceding multiple myeloma diagnosis. Case report and review of the literature 286
Granulomatous mycosis fungoides responsive to gemcitabine 280
[Current aspects of treatment of multiple myeloma] 279
Molecular expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinases in plasmacellular disorders: A molecular panel to nvestigate disease progression 229
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 165
Recurrent Sweet's syndrome in a patient with multiple myeloma 153
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations 150
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 143
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 140
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 139
Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients 133
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant 133
Nephelometric assay of urine free light chains: An alternative and early clinical test for Bence-Jones protein quantification 132
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance 128
Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry? 128
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles: Long-term results of the GITIL/FIL HD 0607 trial 126
Totale 33.612
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.290
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.471 0 0 0 0 0 0 0 0 0 742 881 848
2019/20209.565 685 680 639 781 803 1.025 894 791 859 934 722 752
2020/20215.987 646 713 665 723 633 670 721 581 143 153 284 55
2021/20221.054 43 107 20 76 30 99 44 42 76 87 55 375
2022/20231.592 167 150 77 160 131 349 189 79 137 10 114 29
2023/2024585 52 20 61 20 39 302 33 31 20 7 0 0
Totale 34.838